DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Cagrilintide
GLP-1 agonistRx required

Cagrilintide

Also known as: AM833

Investigational long-acting amylin analog being studied alone and combined with semaglutide (CagriSema).

B
Grade B
Human observational studies
Human studies26
PubMed citations30
Routesubcutaneous
Regulatory (US)Rx required
Last verified2 days ago

Mechanism of action

Long-acting amylin receptor agonist. Acylated for weekly dosing. Suppresses glucagon and slows gastric emptying; complementary to GLP-1 agonism.

Evidence summary

26
Human studies
30
PubMed citations
25
Clinical trials
B
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneous

Side effects & safety

No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Investigational — Phase 3 clinical trials (CagriSema program)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT07527195Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and FunctionNot Yet Recruiting · Phase 1 · Obesity · n=100NCT07411560Single-centre Study Investigating the Role of Long-acting Subcutaneous Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (GIP RA) in Combination With Long-acting Subcutaneous Amylin Receptor Agonist on Gastrointestinal Tolerability in Participants With Overweight or ObesityRecruiting · Phase 1 · Overweight · n=100NCT07220642Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or ObesityActive Not Recruiting · Phase 3 · Obesity · n=300NCT06534411Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or BothActive Not Recruiting · Phase 3 · Diabetes Mellitus, Type 2 · n=1023NCT06221969Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 InhibitorActive Not Recruiting · Phase 3 · Type 2 Diabetes · n=1000NCT06323174Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and ExerciseCompleted · Phase 3 · Type 2 Diabetes · n=189NCT07253285Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or ObesityRecruiting · Phase 3 · Overweight · n=460NCT06131372Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or ObesityCompleted · Phase 2 · Chronic Kidney Disease · n=626NCT07357740A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 DiabetesNot Yet Recruiting · Phase 2 · Diabetes Mellitus, Type 2 · n=400NCT07282613Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 DiabetesNot Yet Recruiting · Phase 3 · Diabetes Mellitus, Type 2 · n=80NCT05567796Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or ObesityActive Not Recruiting · Phase 3 · Obesity · n=3400NCT06388187Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or ObesityActive Not Recruiting · Phase 3 · Obesity · n=300

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 40847076Gu YM, Yuan QN et al. · Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.Acta pharmacologica Sinica (2026)HumanPMID 41328546Verma S, Böttcher M et al. · CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension (Dallas, Tex. : 1979) (2026)HumanPMID 41344603Rejili M, Hussain MS et al. · Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.Vascular pharmacology (2026)HumanPMID 41054801Son JW, le Roux CW et al. · Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.Endocrine reviews (2026)HumanPMID 40544433Garvey WT, Blüher M et al. · Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine (2025)HumanPMID 40022548Madsbad S, Holst JJ · The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.Expert opinion on investigational drugs (2025)HumanPMID 40422561Al Lawati A, Alhabsi A et al. · Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.Diseases (Basel, Switzerland) (2025)HumanPMID 39676787Dutta D, Nagendra L et al. · Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.Indian journal of endocrinology and metabolism (2025)PMID 40865172Rubio-Herrera MA, Mera-Carreiro S · Weight management treatment in obesity.Medicina clinica (2025)HumanPMID 40609154Carvas AO, Leuthardt A et al. · Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.EBioMedicine (2025)HumanPMID 40628316Gabery S, Glendorf T et al. · Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.Life sciences (2025)HumanPMID 40204768Cao J, Belousoff MJ et al. · Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.Nature communications (2025)HumanPMID 40604322Caruso I, Cignarelli A et al. · Incretin-based therapies for the treatment of obesity-related diseases.npj metabolic health and disease (2025)PMID 40544432Davies MJ, Bajaj HS et al. · Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine (2025)HumanPMID 41375628Martínez-Castelao A, Górriz JL et al. · Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.Journal of clinical medicine (2025)PMID 40081498Bailey CJ, Flatt PR et al. · Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides (2025)HumanPMID 39317404Panou T, Gouveri E et al. · Amylin analogs for the treatment of obesity without diabetes: present and future.Expert review of clinical pharmacology (2024)HumanPMID 38338796Eržen S, Tonin G et al. · Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.International journal of molecular sciences (2024)HumanPMID 38753454Gogineni P, Melson E et al. · Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?Expert opinion on pharmacotherapy (2024)HumanPMID 38286487Yao H, Zhang A et al. · Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.BMJ (Clinical research ed.) (2024)Human

Showing 20 of 30 papers. View all on PubMed →